Brought to you by 
Roivant gets rights to HanAll's autoimmune disease candidate
08 Sep 2021
Executive Summary
HanAll BioPharma Co. Ltd. granted Roivant Sciences GMBH exclusive rights to develop, manufacture, and sell its Phase I anti-FcRn monoclonal antibody HL161 for pathogenic IgG-mediated autoimmune diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roivant gets rights to HanAll's autoimmune disease candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice